These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 22538032

  • 41. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D, Paediatric Working Party of UKHCDO.
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [Abstract] [Full Text] [Related]

  • 42. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P, Ghosh K, Shetty S.
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [Abstract] [Full Text] [Related]

  • 43. Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
    Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F.
    Hamostaseologie; 2012 Sep; 32 Suppl 1():S48-51. PubMed ID: 22960877
    [Abstract] [Full Text] [Related]

  • 44. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I, Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [Abstract] [Full Text] [Related]

  • 45. Alloantibodies to factor VIII in haemophilia.
    Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Butenas S, Mann KG, Green D.
    Haemophilia; 2011 Jul; 17(4):636-40. PubMed ID: 21299745
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
    Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB.
    Thromb Haemost; 1987 Dec 18; 58(4):1049-52. PubMed ID: 3127918
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM, van Helden PM, Schwarz HP, Hausl C.
    Br J Haematol; 2007 Jan 18; 136(1):12-25. PubMed ID: 17222196
    [Abstract] [Full Text] [Related]

  • 50. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, Brutman-Barazani T, Lubetsky A, Kenet G.
    Haemophilia; 2013 Sep 18; 19(5):782-9. PubMed ID: 23659442
    [Abstract] [Full Text] [Related]

  • 51. Inhibitors in young boys with haemophilia.
    Lusher JM.
    Baillieres Best Pract Res Clin Haematol; 2000 Sep 18; 13(3):457-68. PubMed ID: 11030045
    [Abstract] [Full Text] [Related]

  • 52. [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin].
    Stiefel M, Pinkwart C, Haase R, Merkel N, Forsberg D, Mauz-Körholz C.
    Hamostaseologie; 2010 Nov 18; 30 Suppl 1():S119-21. PubMed ID: 21042665
    [Abstract] [Full Text] [Related]

  • 53. Late immune tolerance induction in haemophilia A patients.
    Meeks SL, Chapman RL, Kempton C, Dunn AL.
    Haemophilia; 2013 May 18; 19(3):445-8. PubMed ID: 23294063
    [Abstract] [Full Text] [Related]

  • 54. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR, Colvin BT, Ludlam CA, Hill FG, Preston FE.
    Blood Coagul Fibrinolysis; 1996 Mar 18; 7(2):134-8. PubMed ID: 8735802
    [Abstract] [Full Text] [Related]

  • 55. Cytokine profile and FVIII inhibitors development in haemophilia A.
    Oliveira CA, Velloso-Rodrigues C, Machado FC, Carvalho BN, Gentz SH, Martins-Filho OA, Chaves DG.
    Haemophilia; 2013 May 18; 19(3):e139-42. PubMed ID: 23387800
    [Abstract] [Full Text] [Related]

  • 56. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR.
    Br J Haematol; 2018 Feb 18; 180(4):501-510. PubMed ID: 29270992
    [Abstract] [Full Text] [Related]

  • 57. Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
    Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, St-Louis J, Walker IR.
    Haemophilia; 2012 May 18; 18(3):e254-9. PubMed ID: 22077390
    [Abstract] [Full Text] [Related]

  • 58. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D.
    Thromb Haemost; 1994 May 18; 71(5):544-7. PubMed ID: 8091377
    [Abstract] [Full Text] [Related]

  • 59. The natural history of mild haemophilia: a 30-year single centre experience.
    Tagliaferri A, Di Perna C, Riccardi F, Pattacini C, Rivolta GF, Franchini M.
    Haemophilia; 2012 Mar 18; 18(2):166-74. PubMed ID: 21771207
    [Abstract] [Full Text] [Related]

  • 60. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E.
    Haemophilia; 2014 Jan 18; 20(1):83-91. PubMed ID: 24354480
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.